Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance

You may also be interested in...



Lupin Buys Stake In South Africa’s Pharma Dynamics; Aims To Be In Top 3  

MUMBAI - After months of negotiations, Indian generic drug maker Lupin acquired a 60 percent equity stake in South Africa's sixth largest generic drug maker Pharma Dynamics with the goal of joining the top ranks of companies in South Africa in three years

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel